APO RESEARCH · REPORT
Parkinson Disease Drug
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
Product & engineering
Understand the product.
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
Selected research
Industry Research
Parkinson Disease Drug Industry Research Report 2026
Market perspective
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
Report Scope
Read the full market overview
This report quantifies the global Parkinson Disease Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Parkinson Disease Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Parkinson Disease Drug Market by Company
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
F.Hoffmann-La Roche
H.Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Bausch Health
Parkinson Disease Drug Segment by Type
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
Parkinson Disease Drug Segment by Application
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Parkinson Disease Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parkinson Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parkinson Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parkinson Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Parkinson Disease Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Sinemet-CR
- Trastal
- Madopar
- COMT Inhibitor
- Other
Applications
- Under 40 Years Old
- 40-65 Years Old
- Above 65 Years Old
Companies covered
- Merck
- Akorn
- GSK
- Novartis
- Boehringer Ingelheim
- Teva Pharmaceutical
- Abbvie
- Kyowa Hakko Kirin Pharma
- Astellas Pharma
- Desitin Arzneimittel
- Endo Pharmaceuticals
- F.Hoffmann-La Roche
- H.Lundbeck
- Valeant
- Apokyn
- Orion
- Stada Arzneimittel
- US WorldMeds
- Bausch Health
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Parkinson Disease Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Sinemet-CR
- 2.2.3 Trastal
- 2.2.4 Madopar
- 2.2.5 COMT Inhibitor
- 2.2.6 Other
- 2.3 Parkinson Disease Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Under 40 Years Old
- 2.3.3 40-65 Years Old
- 2.3.4 Above 65 Years Old
- 2.4 Assumptions and Limitations
3 Parkinson Disease Drug Breakdown Data by Type
- 3.1 Global Parkinson Disease Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Parkinson Disease Drug Forecasted Market Size by Type (2027-2032)
4 Parkinson Disease Drug Breakdown Data by Application
- 4.1 Global Parkinson Disease Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Parkinson Disease Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Parkinson Disease Drug Market Perspective (2021-2032)
- 5.2 Global Parkinson Disease Drug Growth Trends by Region
- 5.2.1 Global Parkinson Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Parkinson Disease Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Parkinson Disease Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Parkinson Disease Drug Market Dynamics
- 5.3.1 Parkinson Disease Drug Industry Trends
- 5.3.2 Parkinson Disease Drug Market Drivers
- 5.3.3 Parkinson Disease Drug Market Challenges
- 5.3.4 Parkinson Disease Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Parkinson Disease Drug Players by Revenue
- 6.1.1 Global Top Parkinson Disease Drug Players by Revenue (2021-2026)
- 6.1.2 Global Parkinson Disease Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Parkinson Disease Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Parkinson Disease Drug Head Office and Area Served
- 6.4 Global Parkinson Disease Drug Players, Product Type & Application
- 6.5 Global Parkinson Disease Drug Manufacturers Established Date
- 6.6 Global Parkinson Disease Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Parkinson Disease Drug Market Size (2021-2032)
- 7.2 North America Parkinson Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Parkinson Disease Drug Market Size by Country (2021-2026)
- 7.4 North America Parkinson Disease Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Parkinson Disease Drug Market Size (2021-2032)
- 8.2 Europe Parkinson Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Parkinson Disease Drug Market Size by Country (2021-2026)
- 8.4 Europe Parkinson Disease Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Parkinson Disease Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Parkinson Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Parkinson Disease Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Parkinson Disease Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Parkinson Disease Drug Market Size (2021-2032)
- 10.2 South America Parkinson Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Parkinson Disease Drug Market Size by Country (2021-2026)
- 10.4 South America Parkinson Disease Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Parkinson Disease Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Parkinson Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Parkinson Disease Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Parkinson Disease Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck
- 12.1.1 Merck Company Information
- 12.1.2 Merck Business Overview
- 12.1.3 Merck Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.1.4 Merck Parkinson Disease Drug Product Portfolio
- 12.1.5 Merck Recent Developments
- 12.2 Akorn
- 12.2.1 Akorn Company Information
- 12.2.2 Akorn Business Overview
- 12.2.3 Akorn Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.2.4 Akorn Parkinson Disease Drug Product Portfolio
- 12.2.5 Akorn Recent Developments
- 12.3 GSK
- 12.3.1 GSK Company Information
- 12.3.2 GSK Business Overview
- 12.3.3 GSK Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.3.4 GSK Parkinson Disease Drug Product Portfolio
- 12.3.5 GSK Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.4.4 Novartis Parkinson Disease Drug Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Boehringer Ingelheim
- 12.5.1 Boehringer Ingelheim Company Information
- 12.5.2 Boehringer Ingelheim Business Overview
- 12.5.3 Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.5.4 Boehringer Ingelheim Parkinson Disease Drug Product Portfolio
- 12.5.5 Boehringer Ingelheim Recent Developments
- 12.6 Teva Pharmaceutical
- 12.6.1 Teva Pharmaceutical Company Information
- 12.6.2 Teva Pharmaceutical Business Overview
- 12.6.3 Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.6.4 Teva Pharmaceutical Parkinson Disease Drug Product Portfolio
- 12.6.5 Teva Pharmaceutical Recent Developments
- 12.7 Abbvie
- 12.7.1 Abbvie Company Information
- 12.7.2 Abbvie Business Overview
- 12.7.3 Abbvie Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.7.4 Abbvie Parkinson Disease Drug Product Portfolio
- 12.7.5 Abbvie Recent Developments
- 12.8 Kyowa Hakko Kirin Pharma
- 12.8.1 Kyowa Hakko Kirin Pharma Company Information
- 12.8.2 Kyowa Hakko Kirin Pharma Business Overview
- 12.8.3 Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.8.4 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio
- 12.8.5 Kyowa Hakko Kirin Pharma Recent Developments
- 12.9 Astellas Pharma
- 12.9.1 Astellas Pharma Company Information
- 12.9.2 Astellas Pharma Business Overview
- 12.9.3 Astellas Pharma Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.9.4 Astellas Pharma Parkinson Disease Drug Product Portfolio
- 12.9.5 Astellas Pharma Recent Developments
- 12.10 Desitin Arzneimittel
- 12.10.1 Desitin Arzneimittel Company Information
- 12.10.2 Desitin Arzneimittel Business Overview
- 12.10.3 Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.10.4 Desitin Arzneimittel Parkinson Disease Drug Product Portfolio
- 12.10.5 Desitin Arzneimittel Recent Developments
- 12.11 Endo Pharmaceuticals
- 12.11.1 Endo Pharmaceuticals Company Information
- 12.11.2 Endo Pharmaceuticals Business Overview
- 12.11.3 Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.11.4 Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio
- 12.11.5 Endo Pharmaceuticals Recent Developments
- 12.12 F.Hoffmann-La Roche
- 12.12.1 F.Hoffmann-La Roche Company Information
- 12.12.2 F.Hoffmann-La Roche Business Overview
- 12.12.3 F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.12.4 F.Hoffmann-La Roche Parkinson Disease Drug Product Portfolio
- 12.12.5 F.Hoffmann-La Roche Recent Developments
- 12.13 H.Lundbeck
- 12.13.1 H.Lundbeck Company Information
- 12.13.2 H.Lundbeck Business Overview
- 12.13.3 H.Lundbeck Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.13.4 H.Lundbeck Parkinson Disease Drug Product Portfolio
- 12.13.5 H.Lundbeck Recent Developments
- 12.14 Valeant
- 12.14.1 Valeant Company Information
- 12.14.2 Valeant Business Overview
- 12.14.3 Valeant Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.14.4 Valeant Parkinson Disease Drug Product Portfolio
- 12.14.5 Valeant Recent Developments
- 12.15 Apokyn
- 12.15.1 Apokyn Company Information
- 12.15.2 Apokyn Business Overview
- 12.15.3 Apokyn Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.15.4 Apokyn Parkinson Disease Drug Product Portfolio
- 12.15.5 Apokyn Recent Developments
- 12.16 Orion
- 12.16.1 Orion Company Information
- 12.16.2 Orion Business Overview
- 12.16.3 Orion Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.16.4 Orion Parkinson Disease Drug Product Portfolio
- 12.16.5 Orion Recent Developments
- 12.17 Stada Arzneimittel
- 12.17.1 Stada Arzneimittel Company Information
- 12.17.2 Stada Arzneimittel Business Overview
- 12.17.3 Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.17.4 Stada Arzneimittel Parkinson Disease Drug Product Portfolio
- 12.17.5 Stada Arzneimittel Recent Developments
- 12.18 US WorldMeds
- 12.18.1 US WorldMeds Company Information
- 12.18.2 US WorldMeds Business Overview
- 12.18.3 US WorldMeds Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.18.4 US WorldMeds Parkinson Disease Drug Product Portfolio
- 12.18.5 US WorldMeds Recent Developments
- 12.19 Bausch Health
- 12.19.1 Bausch Health Company Information
- 12.19.2 Bausch Health Business Overview
- 12.19.3 Bausch Health Revenue in Parkinson Disease Drug Business (2021-2026)
- 12.19.4 Bausch Health Parkinson Disease Drug Product Portfolio
- 12.19.5 Bausch Health Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst